The company’s first device, which is the MyoVista Wavelet ECG, makes use of AI machine learning to identify cardiac disease that is currently undetectable by traditional ECGs
HeartSciences has received a patent for AI-based ECG assessment of echocardiographic measures of diastolic function of the heart. (Credit: jesse orrico on Unsplash)
Heart Test Laboratories (d/b/a HeartSciences) has received a patent from US Patent and Trademark Office (USPTO) for artificial intelligence (AI) based ECG assessment of echocardiographic measures of diastolic function of the heart.
The US-based medical technology company is engaged in developing AI-based ECG (EKG) to expand and improve the clinical usefulness of ECG by detecting cardiac dysfunction.
The MyoVista Wavelet ECG (wavECG), the first product from HeartSciences, uses AI machine learning to identify cardiac dysfunction that is currently undetectable by traditional ECGs.
The medical technology firm said that the first algorithm of the device is intended to deliver diagnostic data on impaired cardiac relaxation linked to diastolic dysfunction along with full conventional ECG data in a single test.
HeartSciences CEO Andrew Simpson said: “The ECG is a ubiquitous, relatively low-cost, simple and quick test that can be performed in a wide range of clinical settings by a non-specialist clinician or clinical aide. One of the most significant needs in healthcare is the ability to detect cardiac dysfunction early.
“Adding diagnostic information related to cardiac dysfunction to an ECG would not only make it a far more valuable cardiac screening tool, but also addresses a significant unmet need in the market with an estimated 100 million plus ECG tests performed annually in the USA alone.”
Including this patent, the company has been granted a total of eight US patents, bringing the total granted patents, including those from other countries, to 18.
Additionally, the European Patent Office and Israel have granted allowances of other applications submitted by the company.
HeartSciences is waiting for patent approval in various other countries, including Brazil, Canada, India, Mexico, South Korea, and the UAE
HeartSciences chief operating officer Mark Hilz said: “We are committed to patent and intellectual property protection related to our research and development efforts focused on expanding ECG clinical capabilities.
“We believe patent and IP protection is essential, while pursuing novel advancements for ECGs, and are proud to be awarded this valuable patent by the USPTO.”